Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma

BACKGROUND. Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. METHODS. We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Batchelor, Tracy T., Gerstner, Elizabeth R., Ye, Xiaobu, Desideri, Serena, Duda, Daniel G., Peereboom, David, Lesser, Glenn J., Chowdhary, Sajeel, Wen, Patrick Y., Grossman, Stuart, Supko, Jeffrey G.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2017
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464374/
https://ncbi.nlm.nih.gov/pubmed/27663390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now185
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料